Journal of Veterinary Science & Medicine
Immunopathology in Lungs after Intranasal Challenge with Live Virus in EHV-1 Recovered Murine Model of EHV-1 Infection: Lessons Learned From Unexpected Findings
Awan AR1,2,3, Tulp OL1,3 and Field HJ
1University of Health and Humanities, Tortola, British Virgin Islands & Life member, Darwin college, University of Cambridge, UK 2Department of Veterinary Medicine, Madingley Road University of Cambridge, UK 3University of Health and Humanities, Virgin Islands & University of Science, Arts and Technology, Monserrat, BWI
*Address for correspondence: Awan AR, University of Health and Humanities, Tortola, British Virgin Islands & Life member, Darwin college, University of Cambridge, UK; E-mail: Aftab.Awan@cantab.net
Submission: 27 May, 2022 Accepted: 28 June, 2022 Published: 30 June, 2022
Copyright: © 2022 Awan AR, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Equine herpes virus (EHV-1) causes wide-spread infection among horses worldwide. Virus causes respiratory disease, abortion, neonatal death, paresis, retinopathy, viramea and becomes latent. Horses show transient immunity after EHV-1 infection, where immune responses have been observed to decline after a few months of infection and recovered horses are prone to EHV-1 reinfection. Due to transient immune responses, effective and lasting vaccination to EHV-1 remains a challenge. In an HSV murine model, mice provides solid protection and recovered mice could not be re-infected. In this study we infected mice with EHV-1 intra nasally and after five months, mice were re-infected with EHV-1 along with the previously placebo control. It was expected that mice that had recovered would show some level of protection, but in fact they showed unexpectedly severe clinical signs and more deaths on reinfection. Reinfected mice showed severe breathing difficulties, abdominal breathing, weight loss and death compared to mice infected for the first time. The answers to the worst clinical signs came from post-mortem and histopathological findings. Lungs of challenged mice showed severe consolidation and profound infiltration of inflammatory cells such that the normal parenchyma and architecture of lungs were completely lost. The results of this study suggest that immunoreactive pathological mechanisms exists and should be considered in designing intranasal vaccine preparation for EHV-1 and possibly for other respiratory infections.
EHV-1; Infection; Horses
Equine herpes virus type 1 is a respiratory infection and is widespread among horses. This virus causes respiratory disease, causes cell associated viraemia and viraemic cells disseminate the virus to all parts of body. The virus crosses the placenta leading to abortion without premonitory clinical signs, and neonatal death follows [1-8]. The virus also disseminates via viraemia to the CNS leading to myeloencephalopathy (paresis) and retinopathy [9,10]. Equine herpes virus is an alpha herpes virus and becomes latent like other alpha herpes viruses and virus can become be reactivated [1,11,12]. Virus reactivation during periods of stress causing clinical disease and virus shedding has been reported in horses and after administration of corticosteroids [1,5,13]. This virus is so widespread and ubiquitous among horses that it is often difficult to obtain a horse free of EHV- 1 infection to study the pathogenesis of the virus. A murine model was established to study pathogenesis and immune response to this infection [14,15]. This model since then has been widely used to study the pathogenesis of latency abortion, vaccine efficacy and antiviral efficacy [11,17-19].
Natural immunity to this virus after natural infection in horses or experimental infection in specific pathogen foals is short-lived and horses could be re-infected with the virus within 3-5 months of infection. This is a great challenge to control the spread of this infection in horses due to the transient and short-lived nature of the immunity and as a result development of an effective vaccine remains a challenge [2,20-22].
In herpes virus infection the nature of humoral immune response is very complex and many elements of antibody and cell-mediated immune responses are involved in combating the viral infection. Humoral immune responses are important not only in neutralizing extracellular virus but also in cooperating with non-specific effector cells such as natural killer cells, macrophages and antibodydependent cell-mediated cytotoxicity to lyse the infected cells [23-27]. Humoral antibodies are relatively ineffective against intracellular virus dissemination which is characteristic of herpesvirus (HSV) infection, and cell mediated immunity responses have been shown to be effective in limiting HSV infectious [28-30]. Although immunity to herpes virus infection is generally more dependent upon the cellmediated immune responses than humoral responses so far the resistance to the re infection in EHV-1 has only been correlated with the humoral antibody response . An affective immune response requires a synchronization of a number of different physiological and immunological events. Vaccination has been highly successful in control of other viral infections either as an inactivated virus (rabies or Polio) or subunit vaccine (hepatitis B) or yellow fever virus or smallpox vaccine [32-34]. In view of the impressive record of vaccination programs, it seems surprising that attempts to make an effective vaccine against EHV-1 have been very disappointing [22,35-37]. Means to protect the horse from reinfection depends on the antigenic stimulation of antiviral immune response of the horse either with live or inactive vaccine both of which have been tried [1,21]. In either of these studies, only virus isolation was attempted but no attempts were made to study local reaction to lungs on challenge with the virus. Although infections were followed by the appearance of neutralizing and complement fixing antibodies, it appears that the mere presence of these antibodies are not sufficient to guarantee protection and reinfection which could occur in the presence of such antibodies 37. The mechanism how the virus may escape the presence of such antibodies is not yet known.
Most of the information about the pathogenesis of herpes simplex virus (HSV-1 and 2) came from a murine model of HSV infection. One prominent observation noted in mice after HSV infection is that mice become refractory to second HSV infection as immunity developed in this model is typically solid and long lived . Similar responses may be observed in human as subjects who recovered from infection cannot be re-infected easily by similar strains but show symptoms of the disease after reactivation . In has been observed that if one partner is showing reactivation other partner may not contract the disease by intimate contact due to the presence of immunity based on personal observations of married medical student’s subjects (unpublished observations).
In the current study mice were given intranasal live virus and were challenged with the same strain of live virus after five months with the hope to observe protection, when recovered mice were challenged with live virus and dramatic and unexpected findings were observed.
Challenged mice demonstrated worse and more profound clinical signs of illness compared to a group of mice that had been exposed to the virus for the first time. Answers to these unexpected observations came from post-mortem and histo pathological findings. The observations made in this study broaden our understanding of patho physiology and of immune protective and immune reactive mechanisms after live virus challenge. This study has opened the doors to study mechanisms of immunopathological processes in challenge studies and these results are discussed in this communication in relation to formulating any effective vaccine against respiratory viruses.
Mice strain:Female BALB/C mice, were obtained from Bantin & Kingman, UK. Mice were 3-4 weeks old on arrival and were maintained for one week in pre-sterilized plastic cages with fine pine shavings as bedding in a conventional 16/8 hours light cycle at room temperature [20⁰C] to acclimatize to the new surroundings and to minimize the effects of transportation and environmental stress before any regulated procedures were performed. Recovered mice were kept for five months along with uninfected mice from the same batch. Mice were challenged by the same procedure and with the same strain of virus.
Virus strain and tissue culture:The EHV-1 strain Ab4 was used in the study and was a gift from Professor Neil Edington, Royal Veterinary College, London UK. This strain of EHV-1 was originally isolated from a case of equine herpes with neurological complication (paresis). RK-13 cell culture was grown at 37°C in a humidified atmosphere containing 5% CO2. Virus was propagated in the RK-13 cells supplemented with 2% fetal calf serum (FCS) at a low multiplicity of infection (m.o.i.) and the working stock was stored at -70oC in small volumes till used.
Intranasal inoculation of mice:BALB/c female mice were inoculated intranasally (107 p.f.u. per mouse) and observed daily for evidence and progression of infection. Mice were slightly subjected to light anesthesia with ether and 20 μl in volume of virus suspension was placed in each nostril until all was inspired, which occurred over the course of a few seconds. When all mice had been inoculated, the surplus virus was titrated to confirm the dose administered. Mice were euthanized at various time points and their organs were titrated for virus isolation. Heparinized anticoagulated blood was collected and infectious centre assay for viraemia was performed (see below)
Reinfection with live virus previously inoculated with live virus:Twenty-eight BALB c female mice were divided in two groups. Group 1 was inoculated with live virus (107 p.f.u. /mouse) and groups II was inoculated with an uninfected RK cell lysate. Clinical signs were observed in both the groups after inoculation. Group of mice from the same batch were kept which were not inoculated and would be used as primary infection group five months later along with a placebo group control in a challenge study.
Five months after primary infection both groups were inoculated with the same dose of virus (107 p.f.u. / mouse). Their clinical signs were observed as noted. Four mice were killed on day 3 and three mice on day 5 p.i in both the groups along with three mice in negative control group. Their respiratory organs were removed and processed for virus isolation. Anticoagulated blood was also collected under terminal sedation via cardiac puncture in heparinized plastic vials, Buffy coat was collected and infectious centre assay for viraemia was performed to compare viraemia in both groups (see below).
Clinical assessment:Mice were weighed and examined daily to determine the extent of the infection and progression of the infection and the weigh change of each animal individually. Their clinical signs were noted subjectively. Obvious signs such as ruffled fur, crouching in corners or generalized crouching, dyspnea, abdominal breathing, hunched back, athetoid movements and deaths were recorded.
Virus isolation from murine tissues:Groups of mice from each infected group were sacrificed by pentobarbitone sodium injection. The various respiratory organs were minced with scissors and homogenized in an electric blender in 2 ml quantity of Eagles Minimum Essential Medium [EMEM]. The suspension was sonicated for 1 min at 0oC and centrifuged at 3000 rpm for 10 min at 0oC to remove cellular debris. Dilutions of the supernatants were performed in EMEM and sample was inoculated on to confluent RK-13 monolayers. After 45 min of adsorption, EMEM containing 2% fetal calf serum (FCS) and 1% carboxymethyl cellulose (CMC) was added, the monolayer cultures were incubated further and examined after 48 to 72 hours incubation. Monolayer’s were stained with crystal violet and plaques were counted using an inverted Nikon microscope at X6, 12, 25, 50X magnification.
Infectious center assay:Blood (2mg/ml EDTA) was collected direct from the heart following the induction of terminal anesthesia. The blood was centrifuged in microfuge tubes for 5 min and the buffy coat was removed by micropipette. The buffy coat was mixed in 0.9 ml of sterilized distilled water for 1 min to lyse the erythrocytes (flash lysis). The osmotic balance was restored with sterilized [Phosphate Buffered Saline, PBS] PBS X 10 at 1/10 volume of buffy coat suspension in “whirlimix” and centrifuged for 5 minutes to pellet the buffy coat cells. The cells were counted in a haemocytometer and precise number of leucocytes was then added to the confluent RK-13 monolayer. After 30 min of incubation to allow the cells to settle down onto the monolayers, overlay medium with 5% FCS was added and incubation continued for further 5 days. The development of plaques was determined and number of plaques representing infectious centres per 106 cells was counted. One plaque represents one infectious center equivalent. In the absence of cytopathic effect or plaques monolayers were harvested centrifuged at 3K [3,000] rpm for 10 min to pellet the cells. These cell pellets were mixed in virus isolation medium and sonicated in ice cold water in sonic bath for one min and pipetted onto fresh monolayer and incubated for any plaques.
Postmortem findings:Postmortem was performed on mice that died of acute infection or mice that were humanely euthanized along with the controls at various time points. Gross observation like the colour and texture of lungs and any other gross abnormalities were noted and recorded. Any gross appearance of lungs including any consolidation, color change or spongy feel of lung was examined, and findings recorded. Small sections of lungs were fixed in 10% formal saline, paraffin embedded, thin sections were cut and subjected to Haematoxylin and Eosin (H and E) staining to evaluate histopathological changes in both the groups.
Histopathology:Mice were humanely euthanized by pentobarbitone sodium. Small sections of tissues were carefully excised with a scalpel and fixed in 10% formal saline. Tissues were dehydrated and embedded in automatic processor machine in following sequence. Tissues were dehydrated through ascending alcohol concentration at 50%, 70%. 90% and 100% and followed by three changes in acetone for 2 h and two changes in molten paraffin was made and brought back to room temp. Thin sections (5μm) were cut from at approx. 100 μm intervals. In level sectioning (sections were cut after each 5mm) were also performed. These sections were mounted on glass slides and stained using the standard hematoxylin-eosin (H&E) methods of staining.
Clinical signs after primary intranasal inoculation:All infected mice began to demonstrate clinical signs of infection 48 hours after inoculation and by day 3 p.i. all animals were hunched with ruffled fur and infected animal appeared smaller in size and began lose weight which was confirmed by measuring the weights of each mouse daily. Infected mice showed continuous weight reduction for 4 to 5 days and then gradually started to recover. From the third day irregularity in breathing was noted which became progressively worse by day 5 post-infection. About half of the animals demonstrated clinical signs of recovery from infection. Mice were also placebo infected with cells lysate only. None of this group showed any loss in weight or any other clinical signs of reaction to the monolayer cell lysate administered (Figure 1).
Clinical observation after challenge of primary infected mice:Mice started showing clinical signs of the disease on day 2 p.i. However, on day 3, mice were inoculated with live virus and were given live virus again). Challenged group showed more pronounced clinical signs and difficulty in breathing compared to group which was administered virus for the first time. There was a significant reduction in the weight of mice in this group compared to groups who exposed to same virus for the first time and mice looked smaller in appearance (Figure 1). Placebo inoculated mice in primary infection or placebo control in the challenge study did not demonstrate any clinical signs.
Virus isolation:Virus was isolated from respiratory target organs (turbinate bones, and lungs). No significant difference was noted between the two groups (mice exposed to virus for first time or second time) in the turbinate bones on day 3 p.i.but virus titres were significantly lower in challenged group on day 5 post infection. Reduction in the virus tire was found in the lungs on day 3 and on day 5 p.i. in mice that had been inoculated previously with the live virus and this difference was highly significant (p>0.05) and no virus was isolated from challenge group on day 5 p.i (Figure 3, Table 1). This was in contrast to the clinical finding observed where more severe clinical signs like abdominal breathing and deaths were observed in the group of mice that were administered the same strain and dose of live virus five months later compared to groups who has been exposed to the virus for the first time (Figure 1).
Infectious center assays (IC):Anticoagulated blood was collected, and IC assays were performed. Infectious centers were detected in both groups on days 3 and day 5 p.i. The infectious centers were significantly low on day 3 post infection but only two surviving mice were used on day 3 in this group (Table 2). So the level of confidence of significance could not be applied. However on mean values this difference in ICs was comparatively low (8 times lower) to a group of mice previously inoculated with live virus (Table 1). No viraemia was detected in this group on day 5 which was inoculated with virus for the first time but one mouse in challenge groups was positive for viraemia but infectious centers were very low (7 in number) (Table 2).
Postmortem finding:The lungs of mice inoculated with virus for the first time showed typical occasional consolidation but mice who were challenged with the virus five months after recovery from first infection showed more severe signs of consolidation and the lung was so badly consolidated it lost the spongy feel of a lung and showed more solid texture. The answer to the severe consolidation came from histo pathological studies (see below).
Histopathological findings on Primary and Challenge study:Small pieces of lungs were fixed in 10% formal saline to evaluate histopathological changes in both the groups. Lungs of mice that were inoculated with the virus for first time showed typical histopathology of EHV-1 i.e. ballooning, sloughing and desquamation of epithelial cells in primary secondary and tertiary bronchioles and ballooning of alveolar cells (Figure 2). The lungs of mice previously inoculated with live virus and challenged with the same dose of virus demonstrated more pronounced histopathological changes with severe peribronchiolar and perivascular cuffing and local infiltration of inflammatory cells (Figure 4). The infiltration of inflammatory cells in the lungs of challenge mice (live virus plus live virus) was so pronounced that the lung lost its alveolar architecture and, in some locations, it was difficult to identify tissue as lung tissues (Figure 4).
Equine herpes virus (EHV-1) causes respiratory disease, the virus replicates in the respiratory tissues and causes viraemia and abortion, neonatal death, myeloencephalitis, paresis and retinopathy [1,3,6,40-42] . This virus becomes latent, reactivates and is wide-spread among equine worldwide [43-45]. Although the infection in horses followed by the appearance of neutralizing and complements fixing antibodies, the presence of antibody is not sufficient to guarantee protection and reinfection can occur in the presence of such antibodies [1,37,46-48]. Horses show transient immunity after natural or experimental EHV-1 infection and horses could be re infected within 3-5 months of recovery from infection [1,20,37,49]. This virus is so widespread among horses and difficult to obtain horse free of EHV-1 infection to study pathogenesis . In order to study pathogenesis a murine model for equine herpes virus type 1 was established, and a similar pattern of virus replication was observed in the murine model as in equine, including virus replication in the respiratory tissues, viraemia. latency, transient humoral immune response and abortion [14,19,36]. Furthermore, the humoral immune response started to decline after one month of acute infection but cellular immune response is still active after 78 days of acute infection, the latest time point tested .
The murine model of human herpes virus provides valuable information with regard to pathogenesis, immune responses, latency, vaccination, and antiviral efficacy [12,24-26,51,52]. The virus also becomes latent in the trigeminal ganglia. Studies in mice show a similar pattern of virus pathogenesis as seen in humans [24,52-55]. After primary infection there is a solid immune response and mice cannot be reinfected. After primary infection of herpes simplex virus there is a strong immune response and human subjects are not easy to be re-infected with the virus. Similarly, latently infected subjects are protected from a second infection or reinfection from HSV but the virus reactivates and causes disease [12,56]. This is closely observed in married subjects where one partner reactivates and may show the signs of the illness but the other partner may not become reinfected or show any signs of disease perhaps due to primary subclinical infection or low grade primary infection and the presence of immunity hence protection to reinfection (unpublished personal observation of medical student couples).
In the present study mice were challenged with the same dose and same strain of virus five months after primary infection. It was expected that these mice will provide some sort of protection after recovery from the live virus infection but challenged mice demonstrated worse and more severe clinical signs of infection compared to the same age group of mice who were inoculated with the same dose of virus for the first time, albeit there was less virus recovery from the challenge group (Figure 3, Table 1). Virus was isolated from turbinate bones and lungs from both the groups, but the difference was not significant in virus titres recovered from turbinate bone on day 3. But it was significant on day 5. Low virus titres were obtained from the lungs on day 3 and 5 p.i. from group of mice that recovered from primary infection but challenged after 5 months of primary infection (Figure 3). The low virus titres difference was highly significant obtained from the lungs on day 5 from challenged group but this did not warrant the clinical signs observed (Figure 1). Lungs are highly vascular tissues compared to nasal epithelium and perhaps more immunoreactive mechanisms were involved on challenge with live virus in the highly vascular tissues.
Virus isolation from the respiratory organs and level of viraemia indicates that recovered mice from primary infection after five months did support the virus replication, but the amount of virus recovered did not warrant the severe clinical signs and greater deaths observed in the challenge group. Challenged mice showed severe abdominal breathing (dyspnea), mice looked very unwell with ruffled fur, hunched back in the corners of their cages and about 30% died. Severe clinical signs did not warrant the low virus titre solation and answers to unexpected findings came from postmortem when histopathological studies were performed (Figure 3, Table 1).
On post-mortem examination of mice who were challenged with live virus five months after recovery, there was profound consolidation and, in most cases, the spongy feel of the lungs were completely lost and lung tissues appeared very hyperaemic with a liver colouration. More information about the nature of consolidation came from the histopathological observations.
Histopathological findings on lungs of mice that were given the challenge dose of virus five months after recovery from primary infection explained the difficult breathing and other clinical signs. Lung parenchyma of challenged mice was full of inflammatory cells. There was profound infiltration of lymphocytes in tertiary and terminal bronchioles and in many cases infiltration of inflammatory cells were so profound that alveolar sacs and alveolar septae were not visible. At many locations near the terminal bronchioles, it was not even possible to diagnose the tissues as lung tissue due to destruction of alveolar septae and infiltration of lymphocytes (Figure 4b 7 4c).
We believe that these infiltrating cells may be of the same type to the cells which took part in DTH response as reported before. A cell-mediated response was noted previously after 78 days the last time point tested is further evidenced by the histopathological observation of the local infiltration of the inflammatory cells and peri-bronchiolar cuffing in the infected site of lung tissue 12. Before the current in vivo study with histopathological evidence, cellmediated in horses infected with EHV-1 has been mainly restricted to lymphocyte proliferation assays [21,37,57-59]. We believe that current observation also provides unequivocal evidence that cellular part of immune response (immune mediated damage) can cause severe damage or even death and was responsible for the clinical symptoms seen in this study. This infiltration and severity of inflammatory cells was very profound and invading cells damaged the fundamental alveolar architecture in the lung parenchyma. To us these inflammatory cells look like lymphocytes (dark blue big nucleus with little cytoplasm, typical morphology of lymphocytes) at the area of primary, secondary, tertiary and terminally bronchioles and alveoli which are area of virus replication (Awan et al. 1990). It is likely that when virus replicate in these alveolar cells, cells express virus specific peptides in terms of MHC-1 and attract virus specific cytotoxic cells. This probably explains why animals that were challenged after recovery demonstrated more severe clinical signs like difficulty in breathing, look very uunwell, exhibit abdominal breathing and died (Fig. 1). This reaction looks very much like a hypersensitivity reaction in the lungs. We believe that the clinical signs and destruction of local parenchyma at the site of virus replication are due to immunoreactive cells. When virus replicates in the cells, the cells express virus specific MHC peptide and these cells then become the target of virus specific cytotoxic cells or CD8 cells. It is also reported that the herpesvirus glycoproteins are expressed on the membrane of infected cells and they are also targets for the cellular and humoral immune responses [29,51,53,54,60].
This study provides vital information re challenge study in respiratory pathogens not only in EHV-1 but other respiratory viral diseases. As we know and worried re H1NI strain of influenza virus which killed 60 to 100 million people world-wide during the pandemic whether it was in cities or towns or villages during the Spanish flu pandemic. In the first wave of 1916-17 pandemic there was no immunity in the community so the virus hit hard but in the second wave of 1917-18 probably it was the immune response to first infection (cytotoxic cells and ADCC killing) which likely mounted a vigorous attack, caused more damage and took more victims. Historical slides taken from archives (Figure 5) show the effect of influenza virus on the human lung and we made similar histopathological observations in our study (Figure 4b,4c). The figure (Figure 5) does not show typical pathogenesis of influenza virus on the epithelial lining of respiratory cells but in fact it shows severe infiltration of inflammatory cells and damage caused by these cells were so severe that not only alveolar septae were damaged but blood cells could be seen among the infiltrating cells as pathogenesis of influenza virus is rather different from EHV-1 infection (Figure 5). Though, antibiotics could be useful to stop secondary bacterial infection, it is the over excited cellular part of immunity i.e. cytotoxic killer cells or CD8 cells which may be responsible for more deaths and damage [29,30,32,34,61-64]. However, the roles of CD8 cytotoxic cells were not discovered until 1973 so it was not possible to dissect the lungs to check CD8 cells infiltrate in cadaver’s lungs in 1918. We speculate that a similar mechanism in the second wave of the Spanish flu existed in what we observed in respiratory virus challenged infection in a murine model of EHV-1 infection. In the current pandemic of COVID-19 we are also beginning to see a similar trend of greater severity in the current second wave of COVID-19 which affects pneumocytes type II leading to death of these cells and an atypical pneumonia. We also believe that observations we made could be an asset in evaluating the vaccine against Covid 19 as the severity of infection was seen in vaccinated monkeys and such mechanism could be dissected before any damaging effect of vaccine is observed in human subjects.
Many research groups who are working on vaccines for respiratory viruses or respiratory diseases (influenza, RSV or asthma) did the challenge study after intranasal infection and showed protection in their own way. By examining the data presented in conferences, all studies showed weight loss and even death in challenge studies but none could explain this loss of weight as none went any further to investigate the pathological changes seen in challenged groups who lost weight or died. We are fortunate that we went one step further as it was intriguing to find out reasons of severe respiratory signs, abdominal breathing and death. Post mortem findings and histopathological study provided most of the answers and the reason of the clinical signs, weight loss, and death even though fewer viruses were obtained in challenge group.
We believe that cellular part of immunity i.e. cytotoxic cells or CD8 cells and role of immunocomplexes after vaccination (live attenuated, killed, recombinant or mRNA) should be taken into consideration while designing a vaccine as after vaccination both humoral and cellular immunity will become activated . It is the over excited cellular part of immunity along with basophils [via histamine release and cytokine storm) which can cause damage. Over excited cellular part and hence inflammation could be modulated by drugs and in recent COVID-19 cases, anti-inflammatory agents, e.g. dexamethasone, has been found to be effective in reducing the severity of the disease i.e. local inflammation. Non-steroidal drugs of choice could also be of value to control the over expressed profound cellular response as CTL will kill any cells which express foreign epitopes and hence more damage and enable a cascade of inflammation to commence. In order to see the safety of a vaccine, care should be taken that these epitopes do not trigger severe cellular immune responses (CTL, DTH) as this may lead to the destruction of any cell expressing MHC-1 and CD40L on their surface and this may lead to side effects, like fatigue or in worse scenario autoimmune disorders if mimicry to self-molecule is present. Though only respiratory pathogens are discussed in this manuscript, we believe this may applies to other pathogens and vaccines which may trigger a strong cell mediated immune response. It is, therefore, suggested from our findings that cellular immune responses to epitopes is of paramount importance in safety and should be considered in designing and marketing any vaccine to avoid any inadvertent immunopathological damage.
Equine herpes virus (EHV-1) causes wide-spread infection among horses worldwide. After a few months of EHV-1 infection, Immune responses have been observed to decline and recovered horses are prone to EHV-1 reinfection. Due to transient Immunity, effective and lasting vaccination to EHV-1 remains a challenge. In an HSV murine model, mice provides solid protection and recovered mice could not be re-infected. In this study infected mice with EHV-1 intranasally and challenged after five months, showed unexpectedly severe clinical signs and more deaths on reinfection. Reinfected mice showed severe breathing difficulties, abdominal breathing, weight loss and death compared to mice infected for the first time. On histopathological studies Lungs of challenged mice showed severe consolidation and profound infiltration of cells such that the normal parenchyma and architecture of lungs were completely lost. The results of this study suggest that immunopathological mechanisms exist and should be considered in designing any intranasal vaccines.
1. Allen GP, Bryans JT (1986) Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus-1 infections. Prog Vet Microbiol Immunol 2: 78-144.
2. Bürki F, Rossmanith W, Nowotny N, Pallan C, Möstl K, et al. (1990) Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. Vet Q. 12: 80-86.
3. Allen GP, Kydd JH, Slater D, Smith KC (2004) Equid herpesvirus 1 and equid herpesvirus 4 infections. Oxford University Press: 829 - 859.
4. Allen GP (2008) Risk factors for development of neurologic disease after experimental exposure to equine herpesvirus‐1 in horses. Am J Vet Res 69: 1595-1600.
5. Smith KC, Mumford JA, Lakhani KA (1996) comparison of equid herpesvirus‐1 (EHV‐1) vascular lesions in the early versus late pregnant equine uterus. J Comp Pathol 114: 231- 247.
6. Smith KC, Whitwell KE, Blunden AS, Bestbier M, Scase T, et al. (2004) Equine herpesvirus‐1 abortion: Atypical cases with lesions largely or wholly restricted to the placenta. Equine Vet J 36: 79-82.
7. Smith KC, Borchers KA (2001) A study of the pathogenesis of equid herpesvirus‐1 (EHV‐1) abortion by DNA in‐situ hybridization. J Comp Pathol 125: 304-310.
8. Gardiner DW, Lunn DP, Goehring LS, Chiang YW, Cook C, et al. (2012) Strain impact on equine herpesvirus type 1 (EHV-1) abortion models: Viral loads in fetal and placental tissues and foals. Vaccine 30:6564-6572.
9. Goehring LS, van Winden SC, van MaanenC, Sloet van Oldruitenborgh-Oosterbaan MM (2006) Equine herpesvirus type 1-associat.ed myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). J Vet Intern Med 20: 601-607.
10. Galen G, van, Leblond A, Tritz P, LudovicMartinelle L, Pronost,S, et al. (2015) A retrospective study on equine herpesvirus type-1 associated myeloencephalopathy in France (2008-2011). Vet Microbiol 179: 304-309.
11. Field HJ, Awan AR, de la Fuente R (1992) Reinfection and reactivation of equine herpesvirus-1 in the mouse. Arch Virol 123: 409-419.
12. Wildy P, Field HJ, Nash AA (1982) Clinical herpes latency revisited. In: Virus Persistence. Cambridge University Press. 133-136.
13. Gibson JS, Slater JD, Awan AR, Field HJ (1992) Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation. Arch Virol 123: 351-366.
14. Awan AR, Chong YC, Field HJ (1990) The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection. J Gen Virol 71: 1131-1140.
15. Awan AR, Gibson JS, Field HJ (1991) A murine model for studying EHV-1-induced abortion. Res Vet Sci 51: 94-99.
16. Fuente de la R, Awan AR, Field HJ (1992) The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res 18: 77-89.
17. Awan AR, Field, HJ (1993) The effects of phosphonyl methoxyalkyl derivatives studied in a murine model for abortion induced by equine herpesvirus-1 (EHV-1). Antimicrob Agents Chemothe 37: 2478-2482.
18. Field H J, Awan AR, Azmi M, de la Fuente R (1994) Pathogenesis and prophylaxis of equine herpesvirus in a murine model. (Patogenia y profilaxis del herpesvirus equine tipo 1 en un modelo murino). Medicina Veterinaria 11: 235-240.
19. Awan AR, Baxi MK, Field HJ (1995) EHV-1 induced abortion in mice and its relationship to stage of gestation. Res Vet Sci 59: 139 -145.
20. Bryans JT (1969) On immunity of disease caused by equine herpesvirus 1. J Am Med Assoc 155: 294-300.
21. Dutta SK, Shipley WD (1975) Immunity and the level of neutralization antibodies in foals and mares vaccinated with a modified live‐virus rhinopneumonitis vaccine. Am J Vet Res 36: 445- 448.
22. Kydd JH, Townsend HG, Hannant D (2006) The equine immune response to equine herpesvirus‐1: The virus and its vaccines. Vet Immunol Immunopathol 111: 15- 30.
23. Roger-Zisman B, Bloom BR (1974) Immunological destruction of herpes simplex virus -infected cells. Nat 251: 542-543.
24. Nash AA, Field HJ (1980) Quarty-Papafio R: Cell mediated immunity in herpes simplex virus infected mice: induction, characterization and antiviral effect of delayed type hypersensitivity. J Gen Virol 48: 351-357.
25. RoizmanB, Furlong D (1974) The replication of herpesviruses In: Comprehensive virology. Plenum Press: PP: 229-403.
26. SimmonA, Nash AA (1984) Zosteriform spread of herpes simplex virus as model of recrudenscence and its use to investigate the role of immune cells in retention of recurrent disease. J Virol 70: 455-459.
27. Spruance SL (1985) Pathogenesis of Herpes Simplex Labialis: Experimental Induction of Lesions with UV Light. J Clin Microbiol 22: 366-368.
28. Lodmell DL, Niwa A, Hayashi K &Notkins AL (1973) Prevention of cell-to -cell spread of herpes simplex virus by leucocytes. J Exp Med 137: 706-720.
29. Doherty PC &Zinkernagel RM (1975) A biological role for the major histocompatibility antigens. Lancet 1: 1406-1409.
31. Ben-Porat T, DeMarchi J, Lomniczi B, Kaplan AS (1986) Role of glycoprotein of pseudorabies virus in eliciting neutralizing antibodies. Virology 154: 325-334.
32. Ahmed R, Akondy RS (2011) Insights into human CD8 (+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 89: 340-345.
34. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, et al. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183:7919-7930.
35. Katrien CK, Van Cleemput PJ, Laval K, Herman W, Couck,FL, et al. (2019) Equine Herpesvirus 1 Bridles T Lymphocytes To Reach Its Target Organs. J Virol 93: e02098-2118.
36. Tewari D, Love DN, Field HJ (1994) Characterization of Immune Responses to Baculovirus-Expressed Equine Herpesvirus Type 1 Glycoproteins D and H in a Murine Model. J Gen Virol 75: 1735-1741.
37. Wilks CR, CogginsL (1979) Immunity to equine herpesvirus type 1 (rhinopneumonitis) using formalin inactivated virus with various adjuvants. Vet microbiol 4: 209-222.
38. GloriosoMA, Schroder CH, Kumel G, Szcyesiul M, Levine M (1984) Immunogenecity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity. J Virol 50: 805-812.
39. Perna JJ, Mannix ML, Rooney JF, Notkin AL, Straus SE (1987) Reactivation of latent herpes simplex virus infection by ultraviolet light: A human model. JAm Ac Dermatology 17: 473-478.
40. Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzgar SM, et al. (2006) Comparison of the efficacy of inactivated combination and modified‐live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV‐1). Vaccine 24: 3636-3645.
41. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, et al. (2007) A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 3: e160.
42. Hussey GS, Goehring LS, Lunn DP, Hussey SB, HuangT, et al. (2013) Experimental infection with equine herpesvirus type 1 (EHV-1) induces chorioretinal lesions. Vet Res 44: 118.
44. BagustTJ, Pascoe RR, Harden T J (1972) Studies on equine herpesviruses. 3. The incidence in Queensland of three different equine herpes virus infections. Aust Vet J 48: 47-53.
45. Patel JR, Heldens J (2005) Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet J 170: 14-23.
46. Field HJ, Awan AR, Azmi M, Fuente R de la (1994) Pathogenesis and prophylaxis of equine herpesvirus in a murine model. (Patogenia y profilaxis del herpesvirus equine tipo 1 en un modelo murino). Medicina Veterinaria. 11: 235-240.
47. Rosas CT, Goodman LB, von Einem J, Osterrieder N (2006) Equine herpesvirus type 1 modified live virus vaccines: quo vaditis? Expert Rev Vaccines 5: 119-131.
48. Bryans JT, Allen GP (1989) Herpesvirus disease of the horse In: Herpesvirus disease of cattle horse and pig. Kluwer Academic Publisher Boston / Dordrech / London: 176-229.
49. Foote CE, Love D N, Gilkerson JR, Whalley JM (2004) Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet J 36: 341-345.
50. Chong YC, Duffus WPH, Field HJ, Gray D, Awan AR, et al. (1991) The raising of Colostrum deprived foals: Maintenance and assessment of specific pathogen (EHV-1/4) free status. Equine Vet J 23: 111-115.
51. Blacklaws BA, Nash AA, Darby G (1987) Specificity of immune response of mice to herpes simplex virus glycoproteisn B and D constitutively expression in L cell line. J Gen Virol 68: 1103-1114.
52. Awan AR, Harmenberg J, Kristofferson J, Field HJ (1998) Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: a murine model which mimics human recurrent disease. Antivir Res 38: 43-53.
53. Sullivan V, Smith GL (1987) Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (Ig) by recombinant vaccinia virus neutralization of HSV-1 anti-IgG antibody. J Gen Virol 68: 2587-2598.
54. Jennings SR, Lippe PA, Pauza KJ, Spear PG, Pereira L, et al. (1987) Kinetics of expression of herpes simplex virus type 11 specific glycoprotein species on the surface of infected murine simian and human cells: flow cytometric analysis. J Gen Virol 61: 1102-1112.
55. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, et al. (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8: 683-691.
56. Carter CV, Schaefer PA, Teverthia SS (1981) The involvement of herpes simplex virus type 1 glycoprotein in cell mediated-immunity. J Immunol 126: 1655-1660.
57. Gerber JD, Marron AE, Bass EP, Bechenhauer WH 91977) Effect of age and pregnancy on the antibody and cell-mediated immune responses of horses to equine herpesvirus 1. Can J Comp Med 41: 471-478.
58. Dutta SK, MyrupAC, Bumgardner MK (1980) Lymphocyte responses to virus and mitogen in ponies during experimental infection with equine herpesvirus 1. Am Vet Res 41: 2066-2068.
59. Burrows R, Goodbridge D, Denyer M S (1984) Trials of inactivated equid herpesvirus 1 vaccine; challenge with subtype 1 virus. Vet Rec 114: 369-374.
60. Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB (1984) Glycoprotein C of herpes simplex virus acts as a receptor for the Cb Complement antibodies recognize the same antigenic size. Nature 309: 633-635.
61. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
62. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
63. Turner SJ, Diaz G, Cross R, Doherty PC (2003) Analysis of clonotype distribution and persistence for influenza virus-specific CD8+ T cell response. Immunity 18: 549-559.